Presentation to highlight predictive power of CertisAI™ approach to predict and test combination therapies for Glioblastoma Multiforme

It started with back pain.

San Diego, Calif. — November 9, 2023 – Certis Oncology Solutions (Certis), a translational science and precision oncology company, today announced it has been selected as "Overall Immunology Company of the Year" in the third annual BioTech...

Presentation to highlight importance of study design in evaluating anti-tumor effects of immunotherapies in preclinical models

For four decades, the causal link between RAS mutations in cancer – including the KRAS, HRAS, and NRAS genes – has been well-accepted. But for almost as long, oncology drug development has struggled to develop RAS inhibitors, and many had long...

Accelerating the Development of Novel Linebacker Compound

Dedicated Fund Now Open for Private Contributions

Powerful computational tools, such as predictive artificial intelligence (AI) models, are reshaping preclinical research, leading to more optimized and streamlined drug discovery and drug development pipelines.1 In drug discovery, AI can be applied...

Precision oncology (also known as personalized medicine in cancer treatment) is about matching an individual to the optimal therapy for their unique form of cancer. Many people associate personalized medicine with genetic testing. Genomic tumor...

OPTIMIZING BIOMARKER DISCOVERY, MODEL SELECTION AND PRECLINICAL DECISION-MAKING Toronto, ON — April 25, 2023 — In this upcoming live webinar hosted by Xtalks, learn about how artificial intelligence (AI) can bring greater speed and precision to...